Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence.

被引：0
|
作者：
Ubellacker, Jessalvn M. [1 ]
Baryawno, Ninib [2 ,3 ]
Severe, Nicolas [2 ,3 ]
DeCristo, Molly J. [1 ]
Sceneay, Jaclyn [4 ]
Haider, Marie-Therese [5 ]
Rhee, Catherine S. [2 ,3 ]
Qin, Yuanbo [4 ]
Holen, Ingunn [5 ]
Gregory, Walter M. [6 ]
Brown, Janet E. [7 ]
Coleman, Robert E. [7 ]
Scadden, David T. [2 ,3 ]
McAllister, Sandra S. [4 ]
机构：
[1] Harvard Med Sch, Dept Med, Boston, MA USA
[2] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[5] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England
[6] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England
[7] Univ Sheffield, Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England
来源：
MOLECULAR CANCER RESEARCH | 2018年 / 16卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B13
引用
收藏
页码：68 / 69
页数：2
相关论文
共 36 条
  • [1] Serum Levels of G-CSF and IL-7 in Iranian Breast Cancer Patients
    Bordbar, Elahe
    Malekzadeh, Mahyar
    Ardekani, Mehdi Taghipour Fard
    Doroudchi, Mehrnoosh
    Ghaderi, Abbas
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 5307 - 5312
  • [2] The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels
    Pollmacher, T
    Fenzel, T
    Mullington, J
    HinzeSelch, D
    PHARMACOPSYCHIATRY, 1997, 30 (04) : 118 - 121
  • [3] Addition of granulocyte-colony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells
    Altundag, K
    Altundag, O
    Elkiran, ET
    Cengiz, M
    Ozisik, Y
    MEDICAL HYPOTHESES, 2004, 63 (01) : 56 - 58
  • [4] Treatment of advanced refractory breast cancer with docetaxel alternating with epirubicin and cyclophosphamide (EC)+G-CSF
    Valencak, J
    Kornek, GV
    Haider, K
    Raderer, M
    Kwasny, W
    Bareck, E
    Weinlander, G
    Depisch, D
    Kovats, E
    Scheithauer, W
    ANNALS OF ONCOLOGY, 1998, 9 : 180 - 180
  • [5] Treatment of advanced refractory breast cancer with docetaxel alternating with epirubicin and cyclophosphamide (EC)+G-CSF
    Weinländer, G
    Kornek, GV
    Haider, K
    Raderer, M
    Valencak, J
    Kwasny, W
    Bareck, E
    Depisch, D
    Kovats, E
    Scheithauer, W
    BRITISH JOURNAL OF CANCER, 1998, 78 : 10 - 10
  • [6] Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model
    HellstromLindberg, E
    Negrin, R
    Stein, R
    Krantz, S
    Lindberg, G
    Vardiman, J
    Ost, A
    Greenberg, P
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (02) : 344 - 351
  • [7] G-CSF and IL-3 levels in CML patients: Relationship to disease stage and response to treatment.
    Liakopoulou, E
    Allan, E
    Jiang, X
    Jorgensen, H
    Graham, S
    Richmond, L
    Alcorn, M
    Pearson, C
    Eaves, C
    Brummendorf, T
    O'Brien, S
    Eaves, A
    Holyoake, T
    BLOOD, 2000, 96 (11) : 351A - 351A
  • [8] Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer
    De Rosa, L
    Lalle, M
    Perillo, A
    Pierelli, L
    Salerno, MG
    Cortesi, E
    Martelli, O
    Pandolfi, A
    Amodeo, R
    Marzetti, L
    Mancuso, S
    Scambia, G
    ANTICANCER RESEARCH, 2001, 21 (2B) : 1367 - 1370
  • [9] A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy
    Sanchiz, F
    Milla, A
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) : 52 - 56
  • [10] RESEARCH ON THE SHIFT OF BONE-MARROW-SUPPRESSION AND THE USE OF G-CSF DUE TO FEC100 TREATMENT FOR BREAST CANCER
    Nakamura, K.
    Onikubo, T.
    Nakamura, M.
    ANNALS OF ONCOLOGY, 2013, 24 : 73 - 73
1234